Aardvark Therapeutics, Inc.
AARD· Nasdaq
AARDAardvark Therapeutics, Inc.
Filed May 7, 2026 · 10-Q · 37 days after period end · 0001193125-26-210675
| Metric | Q1 2026 | Q1 2025 | Q1 2024 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | — |
| Net Income | -$21.59M | -$9.31M | -$2.18M |
| EPS Diluted | -$0.99 | -$0.71 | -$0.55 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aardvark Therapeutics, Inc. · CIK 1774857 · Engraved from SEC EDGAR
ended Mar 31, 2026 · filed May 7, 2026 · 37 d after period end
